For example, tumors typified by certain genetic alterations (e.g., POLE or POLD mutations), transcriptomic profiles (e.g., IFN-γ-related RNA signatures), tumor microenvironment constituents (e.g., enrichment of tumor infiltrating lymphocytes), and microbiota (e.g., EBV infection, gut flora diversity) exhibit higher sensitivity to immunotherapy [16,42,43,44,45,46]. This evidence concerns the gene POLE and neoplasm.